Holen Sie sich die Stockscreener-App
1.42
1.43%
0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.40
Offen:
$1.42
24-Stunden-Volumen:
1.01M
Relative Volume:
0.42
Marktkapitalisierung:
$516.03M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.775
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+0.00%
1M Leistung:
+6.77%
6M Leistung:
+101.88%
1J Leistung:
-22.83%
1-Tages-Spanne:
$1.40
$1.46
1-Wochen-Bereich:
$1.36
$1.53
52-Wochen-Spanne:
$0.2836
$2.08
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.42 | 508.76M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFsJuly 2025 Institutional & Consistent Profit Alerts - newser.com
What candlestick patterns are forming on Lexicon Pharmaceuticals Inc.Market Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsQuarterly Profit Summary & Weekly High Return Forecasts - newser.com
Using data tools to time your Lexicon Pharmaceuticals Inc. exitJuly 2025 Outlook & Technical Pattern Alert System - newser.com
Published on: 2025-10-24 01:54:11 - newser.com
Is Lexicon Pharmaceuticals Inc. building a consolidation baseDip Buying & Safe Swing Trade Setups - newser.com
Published on: 2025-10-21 14:44:52 - newser.com
Full technical analysis of Lexicon Pharmaceuticals Inc. stockEntry Point & Safe Entry Zone Tips - newser.com
What analysts say about Lexicon Pharmaceuticals Inc stockTrading Volume Trends & Double Or Triple Investment - earlytimes.in
Macro Review: Is Lexicon Pharmaceuticals Inc. stock a defensive play in 20252025 Market Overview & Comprehensive Market Scan Reports - nchmf.gov.vn
How analysts rate Lexicon Pharmaceuticals Inc. stock todayWeekly Trend Recap & Long-Term Growth Stock Strategies - nchmf.gov.vn
Activity Recap: How analysts rate Lexicon Pharmaceuticals Inc. stock todayJuly 2025 EndofMonth & Community Trade Idea Sharing - nchmf.gov.vn
Is Lexicon Pharmaceuticals Inc. stock a defensive play in 20252025 Pullback Review & AI Optimized Trading Strategy Guides - nchmf.gov.vn
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastSector Leadership Analysis & Affordable Growth Strategies - earlytimes.in
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times
Lexicon Pharmaceuticals Advances 10mg Pilavapadin to Phase 3 | LXRX Stock News - Stock Titan
Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat
Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat
Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus
Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛
Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com
Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):